ascopubs.org12d
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
ascopubs.org8d
Performance of a blood-based test for colorectal cancer screening adjusted to the US census age and sex distribution.
Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13). Single-cycle neoadjuvant ...
ascopubs.org8d
Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks.
Incidence trends, demographic disparities, and survival outcomes of gastrointestinal malignancies in young adults: A focus on stomach and pancreatic cancers. Safety and efficacy of first-line ...
ascopubs.org9d
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...
ascopubs.org5d
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...
ascopubs.org8d
Exploring Nectin-4 expression in hepatocellular carcinoma.
Exclusive liver invasion as prognostic indicator in T3 gallbladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full ...
ascopubs.org8d
Neoadjuvant immunotherapy for locally advanced/metastatic mismatch repair deficient colorectal cancer: A two-year institutional experience.
A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry. This is an ASCO ...
ascopubs.org4d
What Are the Real Pros of Real-Time PROs (Patient-Reported Outcomes)?
What Are the Real Pros of Real-Time PROs (Patient-Reported Outcomes)? The following represents disclosure information provided by the author of this manuscript. All relationships are considered ...
ascopubs.org4d
CFO: Calibration-Free Odds Bayesian Designs for Dose Finding in Clinical Trials
Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Calibration-free odds type ...
ascopubs.org6d
Evaluating immune cell abundance across hepatocellular carcinoma disease stages I-III: Findings from TCGA analysis.
Analysis of gut and mucosal microbiomes in patients with extrahepatic cholangiocarcinoma.
ascopubs.org5d
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma Individual patient data of neoadjuvant RCTs with available ...
ascopubs.org8d
Phase 1b study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Evaluating the immunological effects.
Predictive role of circulating tumor DNA for locally advanced esophageal squamous cell carcinoma before surgery. Concordance between human epidermal growth factor receptor 2 (HER2) status by ...